Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Key facts

Study ID

NCT00364091

Run by

Vistakon Pharmaceuticals

People needed

365

Starts

2006-08-01

Last updated by the study team

2011-09-27

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• history of positive diagnostic test for ragweed within the past 2 years;
• positive bilateral response to ragweed as induced by conjunctival allergen challenge

You may not qualify if…

• ocular infection;
• history of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
• moderate to severe asthma;
• dry eye syndrome;
• history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease;
• pregnancy or lactation

Where it is running

• Study site — Louisville, Kentucky, United States
• Study site — North Andover, Massachusetts, United States
• Study site — Creve Coeur, Missouri, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.